Since this protein is one of most important members involved in the RAF/MEK/ERK signaling pathway, MAPK14 is associated with sorafenib, which is a drug used for the treatment of advanced renal cell carcinoma (primary kidney cancer) and advanced hepatocellular carcinoma (primary liver cancer). This evidence concerns the gene MAPK14 and kidney cancer.